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Hormone replacement therapy is associated with improved
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Objectives: The effect of hormone replacement therapy on cardiovascular events in
postmenopausal women is controversial. We investigated the roles of sex and
hormone replacement status in female patients undergoing coronary artery bypass
grafting.
Methods: We reviewed the records of 4259 consecutive patients aged 55 years or
older who underwent primary elective isolated coronary artery bypass at our
hospital between May 1996 and September 2001.
Results: Female sex with hormone replacement therapy was an independent pre-
dictor of decreased mortality, regardless of age. Mortality was 6.7% (61/905) for
women not receiving hormone replacement therapy, 2.3% (6/256) for hormone
replacement therapy recipients, and 2.7% (82/3098) for men (P  .01 for all
comparisons). Of the characteristics examined, multivariate analysis indicated that
independent predictors of mortality were advanced age, previous congestive heart
failure, class IV angina, and female sex without hormone replacement (P  .005).
Independent predictors of survival included use of an internal thoracic artery graft
and white ethnicity. There were no significant intergroup differences in the inci-
dence of nonfatal, morbid postoperative events.
Conclusions: Postmenopausal women undergoing coronary artery bypass had a
significantly improved in-hospital survival if they had been receiving hormone
replacement therapy. The improved survival might be related to one or more of the
numerous cardiovascular effects of estrogen that are considered beneficial. A
prospective randomized trial is needed to validate the observation that hormone
replacement therapy is protective in this setting.
Among patients undergoing coronary artery bypass grafting(CABG), the in-hospital mortality has consistently been higher inwomen than in men.1,2 Explanations for this difference havefocused primarily on the more frequent comorbidity that is pre-dictive of a poor outcome in women. In some studies statisticaladjustment of mortality for risk-factor profiles eliminated female
sex as an independent predictor.1,3,4 In the largest CABG database, however, female
sex remained an independent predictor, despite risk-factor adjustment.2
None of these studies explored the possible role of hormone replacement therapy
(HRT) in perioperative mortality. Such therapy is not recommended for secondary
prevention of cardiovascular disease and is controversial, even for primary preven-
tion.5-7 Nevertheless, investigators have described numerous cardiovascular effects
of estrogen that are considered beneficial,8 including attenuation of adverse re-
sponses to endoluminal vascular trauma.9 Limited clinical studies suggest that HRT
in postmenopausal women favorably affects long-term outcome after the endolu-
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minal trauma of coronary angioplasty and CABG.10-12
Shackelford and colleagues13 recently assessed the mortal-
ity after isolated CABG in 734 consecutive women, of
whom 102 had received HRT preoperatively. On univariate,
but not multivariate, analysis, the in-hospital mortality was
significantly lower in the women who received HRT (2.7%
vs 7.4%). The present study was undertaken to obtain ad-
ditional data regarding the attractive hypothesis that HRT
improves the in-hospital outcomes of cardiovascular surgi-
cal procedures that induce endoluminal vascular injury.
Methods
This retrospective analysis was performed on a comprehensive,
prospectively collected database that included all patients treated
at the Texas Heart Institute since 1993. (Completed patient charts
are routinely abstracted, and data relating to risk factors and
outcomes are entered into the database.) This study included 4259
consecutive men and women aged 55 years or older who under-
went primary elective CABG with cardiopulmonary bypass be-
tween May 1996 and September 2001, without concomitant pro-
cedures, such as valve or ventricular aneurysm repair. The 55-year
cut-off point for postmenopausal status is widely used.12,14-16
Female patients were classified as receiving HRT if oral or trans-
dermal estrogen replacement or combined estrogen-progesterone
replacement therapy was recorded in the physician’s notes or the
nurse’s patient-admission assessment, which includes a list of
current medications. All other patients were classified as not re-
ceiving HRT. For female patients receiving HRT, the first two
thirds (172/256) of the hospital records were rechecked to verify
documentation of HRT status at the time of admission; no errors
were found. Duration of HRT was not recorded in the database. In
no instance, however, was HRT initiated by the admitting physi-
cian.
All analyses involved 3 groups: women not receiving HRT,
women receiving HRT, and men. These were the primary predictor
variables, with women without HRT serving as the reference
group. Other potential preoperative predictor variables included
age, body mass index, race (white vs nonwhite), preoperative
ejection fraction, number of diseased coronary vessels, diabetes
(with or without insulin dependence), history of congestive heart
failure, unstable angina, previous myocardial infarction, tobacco
use, peripheral vascular disease with or without intervention, hy-
pertension, chronic obstructive pulmonary disease or asthma, or
dialysis-dependent renal failure. The potential influence of preop-
erative concurrent therapy, including angiotensin-converting en-
zyme inhibitors, calcium-channel blockers, -blockers, antihyper-
lipidemic agents, and aspirin, was also included in the analysis.
Potential perioperative predictor variables included the number of
vessels bypassed and use of an internal thoracic artery (ITA) graft.
The primary outcome variable was in-hospital mortality. Sec-
ondary outcome variables included major perioperative morbidity,
such as myocardial infarction, use of an intra-aortic balloon pump,
stroke, new onset of renal failure necessitating dialysis, postoper-
ative infection, respiratory insufficiency (when diagnosed by a
pulmonary specialist), postoperative bleeding necessitating re-ex-
ploration, and thromboembolic events (deep venous thromboem-
bolism or pulmonary embolism). Univariate associations between
potential predictors and outcome were assessed by means of 2
analysis, followed by stepwise logistic modeling, which examined
all significant predictors (P  .10) for all groups.
Results
Of the 4259 patients in this study, 1161 were women, of
whom 256 (22.0%) were receiving HRT at hospital admis-
sion. This incidence of HRT is similar to the 20% estrogen-
use rate reported by the National Center for Health Statis-
tics.17 Of the 256 HRT recipients, 85% took conjugated
estrogen (Premarin) or estradiol (Estrace or Estraderm)
only. The remainder took a combination of conjugated
estrogen and medroxyprogesterone acetate (Prempro, Prem-
phase, or Premarin plus Provera).
The in-hospital mortality for all patients was 3.5%. For
women not receiving HRT, the mortality was 6.7% com-
pared with 2.3% for women receiving HRT and 2.7% for
men (P  .008 compared with HRT recipients and P 
.0001 compared with men by means of univariate analysis).
Multivariate analysis confirmed that female sex without
HRT was an independent predictor of increased in-hospital
mortality (P  .005).
Preoperative patient characteristics, intraoperative data,
and length of hospital stay for the 3 groups were compared
(Table 1). Compared with women receiving HRT, the
women not receiving HRT were older (by 2.4 years, P 
.0001), were more likely to be nonwhite (P  .0001), were
more likely to have a history of diabetes (P  .007) and
congestive heart failure (P  .002), had more diseased
vessels (P  .0002), and had more vessels bypassed (P 
.002). Women receiving HRT were more often smokers
(P  .04), had a higher incidence of hypertension (P .04),
and had more frequent use of an ITA graft (P  .003).
Multivariate analysis for independent predictors of mor-
tality indicated that female sex without HRT significantly
predicted higher in-hospital mortality (Table 2). Other in-
dependent predictors were advanced age, history of conges-
tive heart failure, and class IV angina. Independent predic-
tors of survival included use of an ITA graft and white race
(Table 2).
The mortality of all the women in this study was exam-
ined in terms of precipitating and ultimate causes to identify
possible differences in patterns of mortality between women
receiving and not receiving HRT. The result was unreward-
ing because of the small number of deaths in the HRT group
(n  6). In both groups approximately 50% of the deaths
were primarily cardiac (ie, related to cardiogenic shock,
myocardial infarction, arrhythmia, or congestive heart fail-
ure), and 13% were primarily related to the central nervous
system (stroke and encephalopathy). Other causes of death
included respiratory failure, renal failure, gastrointestinal
complication, hemorrhage, sepsis, pulmonary embolus, and
multiorgan system failure. The pattern of postoperative
morbidity among the 3 groups was similarly compared
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(Table 3). There were no significant differences in morbid-
ity related to HRT.
Discussion
Women undergoing CABG consistently have a higher op-
erative mortality than men,1,2 but there is no agreement as to
whether female sex, per se, is an independent risk factor. In
several reports that have shown a higher in-hospital mortal-
ity in women, investigators have used various statistical
models to adjust for body surface area, coronary artery size,
or risk-factor profile.1,3,4 With such adjustments, the male-
female difference tended to lose significance. However, in
the largest database, which included 97,153 women and
247,760 men who underwent isolated CABG between 1994
and 1996, women still had a significantly higher operative
mortality (4.5% vs 2.6%),2 even when confounding risk
factors were adjusted. This observation was reaffirmed in a
reanalysis of these data.18 In none of the studies cited above
was HRT examined as a predictor of mortality. Our data
support female sex as an independent predictor of mortality
and further suggest that HRT reduces risk in women to that
in men.
The effect of HRT on the cardiovascular system is not
clear.5-8,19A large number of observational studies sug-
gested that HRT offers substantial cardiovascular bene-
fits.20-22 However, the results of large, prospective, random-
ized controlled clinical trials designed to study the effects of
HRT in women with or without known coronary artery
disease—the Heart and Estrogen/Progestin Replacement
Study,14 the Estrogen Replacement and Atherosclerosis tri-
al,15 and the Women’s Health Initiative study7— showed no
significant benefit and raised the possibility of short-term
increases in risk. For secondary prevention of cardiovascu-










Age (y) 68.0 7.8 70.4 8.0† 67.1 7.7
Body mass index (kg/m2) 27.6 5.5 28.1 6.2 27.9 5.0
White ethnicity (%) 85.2 69.8‡ 72.2‡
Diabetes (%) 29.3 38.6† 31.1
Ejection fraction (%) 53.0 11.8 51.4 14.3 48.7 13.4†
NYHA class IV angina (%) 13.3 16.0 11.3§
No. of vessels diseased* 1.7 0.9 1.9 1.0 2.1 0.9
History of:
Tobacco use (%)* 40.0 33.0 53.2
Congestive heart failure (%) 20.7 30.8† 19.0
Previous MI (%) 35.9 39.1 40.5
Hypertension (%)* 84.8 79.1 70.2
Peripheral vascular disease (%) 24.2 28.5 19.5§
Renal failure (%) 0.39 0.11 0.23
COPD (%) 10.9 12.4 10.3
Preoperative IABP (%) 1.2 1.1 1.2
Use of an ITA graft (%)* 84.4 75.7 89.7
Duration of CPB (min) 58.1 32.9 62.5 36.2 64.5 32.7‡
No. of vessels bypassed* 2.7 1.0 2.9 1.1 3.3 1.1
Postoperative hospital stay (d) 9.8 7.7 10.2 7.7 9.4 8.7§
Values are presented as means  SD. NYHA, New York Heart Association; MI, myocardial infarction; COPD, chronic obstructive pulmonary disease; IABP,
intra-aortic balloon pump; CPB, cardiopulmonary bypass.
*P  .05 for all comparisons among groups.
†P  .05 versus both other groups.
‡P  .05 versus women receiving HRT.
§P  .05 versus women not receiving HRT.
TABLE 2. Multivariate preoperative predictors of mortality
or survival after CABG
OR 95% CI P value
Predictors of mortality
Age 75 y 4.0 2.3-6.8 .0001
Age 65-75 y 2.5 1.5-4.3 .0004
Previous congestive heart failure 3.4 2.4-4.9 .0001
Class IV angina 1.7 1.1-2.7 .02
Female sex without HRT 1.7 1.2-2.5 .004
Predictors of survival
Use of an ITA graft 0.6 0.4-0.9 .006
White race 0.6 0.4-0.8 .003
Only predictor variables significant in the multivariate analysis are in-
cluded (see the “Methods” section for list of all variables analyzed). OR,
Odds ratio; CI, confidence interval.
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lar events, the latest American Heart Association recom-
mendations state that combinations of estrogen plus proges-
terone should not be initiated for this purpose.5,7 Definitive
evidence regarding the benefits and risks of estrogen ad-
ministered alone (without progesterone) for primary preven-
tion of cardiovascular disease should emerge from the on-
going branch of the Women’s Health Initiative trial
involving women who had a hysterectomy, to be completed
in 2005.7
It is possible that the benefits of HRT are most evident in
the presence of vascular injury, as noted in numerous lab-
oratory studies.9,23-28 It has been clearly shown that endo-
thelial cells and vascular smooth muscle cells possess es-
trogen receptors and that estrogen modulates the vascular
responses to numerous endogenous hormones. In animal
models of endoluminal injury of normal blood vessels,
estrogen inhibits the hyperproliferation resulting from acti-
vation of adventitial cells and their migration toward the
lumen.29 In the rat model with a balloon-injured common
carotid artery, Oparil and colleagues9,23-28 showed that es-
trogen inhibited neointima formation by affecting all 3
layers of the vascular wall, inhibiting medial smooth muscle
cell migration and proliferation, stimulating regrowth of the
endothelium, and inhibiting adventitial-cell migration into
neointima. Other data suggest women receiving HRT have
greater endogenous fibrinolysis30 and that estrogen modifies
the inflammatory response to reperfusion injury in ani-
mals.31,32 It is not at all clear which aspect of estrogen’s
action might mediate a benefit in the presence of vascular
injury.
Some clinical data support the benefits of estrogen in the
presence of vascular injury. Shlipak and colleagues16 stud-
ied 114,724 women aged 55 years or older with confirmed
myocardial infarction participating in the National Registry
of Myocardial Infarction 3. At hospitalization, 7353 (6.4%)
reported current use of HRT. Unadjusted mortality was
7.4% in users of HRT and 16.2% in nonusers (odds ratio,
0.41; confidence interval, 0.36-0.43). O’Keefe and coau-
thors10 retrospectively studied 337 postmenopausal women
undergoing elective percutaneous transluminal coronary an-
gioplasty, of whom 137 were consecutive women receiving
long-term estrogen therapy at the time of percutaneous
transluminal coronary angioplasty. The control group com-
prised 200 nonusers of estrogen who were computer
matched to the estrogen group. The 7-year survival rate was
significantly better in the estrogen group (93% vs 75%, P
.001), and the cardiovascular event rate was significantly
lower in the estrogen group.10 Also, Khan and associates11
studied 129 women who underwent stenting of a single
coronary artery. Estrogen treatment significantly reduced
the need for repeat-target lesion revascularization (14/49
HRT users vs 30/56 nonusers). Sullivan and coworkers12
studied 1098 postmenopausal women undergoing CABG.
Although only 92 (8.4%) women were receiving HRT at the
time of CABG, they had a 5-year survival rate of 98.8%
compared with 82.3% for non-HRT users and a 10-year
survival rate of 81.4% versus 65.1%, respectively. In a
multivariate analysis of long-term survival after CABG, use
of HRT remained a significant predictor of survival. More
recently, Shackelford and colleagues13 retrospectively stud-
ied 734 consecutive postmenopausal women undergoing
isolated CABG from 1992 to 1997, of whom 102 (13.9%)
received estrogen. Univariate analysis showed that the peri-
operative mortality was significantly lower in the women
receiving HRT (2.7% vs 7.4%), but stepwise logistic regres-
sion failed to confirm the significance of HRT use. Our
mortality data from a larger population are strikingly similar
to these. In our data, however, female sex with HRT was a
significant independent predictor of a lower in-hospital mor-
tality after isolated CABG.
Our study has several limitations apart from those inher-
ent in a retrospective single-institution analysis. HRT data
were not routinely recorded before May 1996. Neither were
specific doses recorded. Despite a large sample of 4259
patients, only 27.3% were women, and of these, only 22%
were receiving HRT. These small numbers decreased the
statistical power for detecting differences in patterns of
outcome that might have provided clues to the mechanism
of benefit by HRT. A further limitation common to obser-
vational studies such as this one is that the apparent benefit










Myocardial infarction 11 (4.3%) 29 (3.2%) 101 (3.3%)
Intra-aortic balloon pump 4 (1.6%) 5 (0.6%) 21 (0.7%)
Stroke 8 (3.1%) 44 (4.9%) 112 (3.6%)
Renal failure 2 (0.8%) 21 (2.3%) 43 (1.4%)
Any infection 19 (7.4%) 85 (9.4%) 208 (6.7%)*
Respiratory failure 30 (11.7%) 97 (10.7%) 310 (10.0%)
Postoperative reoperation for bleeding (%) 10 (3.9%) 30 (3.3%) 138 (4.5%)
Thromboembolic event 1 (0.4%) 8 (0.9%) 8 (0.7%)
*P  .05 versus women not receiving HRT.
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of HRT could be the result of selection bias not apparent
from the characteristics we have recorded. Our group of
women receiving HRT compared with the group not receiv-
ing HRT were 2.4 years younger, were more often of white
ethnicity, had less diabetes, had less congestive heart fail-
ure, had fewer diseased vessels, and were more frequently
given an ITA graft. Conversely, they were more often
smokers, had more hypertension, and had fewer vessels
bypassed. Even though multivariate analysis identified age,
congestive heart failure, class IV angina, white race, and use
of an ITA in addition to HRT as independent predictors of
mortality versus survival, a selection bias could account for
the apparent benefit of HRT. These limitations could be
further resolved by a prospective multi-institutional study
designed to acquire larger numbers of female patients with
more balanced comorbidity and additional characteristics
recorded. A possible reduction in the CABG mortality and
better outcome after angioplasty warrants such an effort.
After CABG in patients aged 55 years or older, women
receiving HRT had a significantly lower in-hospital mortal-
ity than did women not receiving HRT. In fact, mortality
after CABG in female HRT recipients was similar to that of
men. We postulate that one or more of the cardiovascular
actions of estrogen might benefit the coronary response to
endoluminal injury of CABG. Randomized prospective tri-
als are required to address the broader issues of HRT and
cardiovascular health.
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